Form: CORRESP

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

December 6, 2022

 

Abeona Therapeutics Inc.

1330 Avenue of the Americas, 33rd Floor

New York, NY 10019

 

December 6, 2022

 

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F Street NE

Washington, DC 20549

Attention: Tim Buchmiller

 

VIA EDGAR

 

Re:

Abeona Therapeutics Inc.

Registration Statement on Form S-3

Filed on December 1, 2022

File No. 333-268619

 

Dear Mr. Buchmiller:

 

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-268619) (the “Registration Statement”) of Abeona Therapeutics Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Eastern time, on December 12, 2022, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Morgan, Lewis & Bockius LLP, by calling Brian V. Soares at (202) 739-5482.

 

  Very Truly Yours,
     
  Abeona Therapeutics Inc.
     
  By: /s/ Joseph Vazzano
  Name: Joseph Vazzano
  Title: Chief Financial Officer

 

cc: John J. Concannon III, Morgan, Lewis & Bockius LLP